Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) receptor , is showing promising data in preliminary clinical assessments . Ongoing https://bookmarkproduct.com/story21475253/retatrutide-emerging-studies-and-possible-therapeutic-uses